Arca
Skip to content
Tools
Tools

ABCC8, KCNJ11: Sulfonylurea receptor 1, Kir6.2

Complex in Homo sapiens that 12 drugs act on.

  • Drugs that act on it: 12
  • Approved: 10
  • In phases 1 to 3: 2
  • Sponsors: 9

Who is on it, and how far along

Every drug ChEMBL records acting on ABCC8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 11
  • Other 1

Approved10

  • Repaglinide
  • Gliclazide
  • Glimepiride
  • Glyburide
  • Glipizide
  • Tolbutamide
  • Acetohexamide
  • Chlorpropamide
  • Nateglinide
  • Tolazamide

Phase 32

  • Mitiglinide
  • Mitiglinide calcium dihydrate

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Elixir Pharmaceuticals18%
      • Jiangsu Simcere Pharmaceutical Co., Ltd.18%
      • Kissei Pharmaceutical Co., Ltd.18%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sulfonylurea receptor 1, Kir6.2 blocker.
      RepaglinideApprovedGemini LabsSmall moleculeBlocker9
      GliclazideApprovedMerck & Co. (MSD)Small moleculeBlocker5
      GlimepirideApprovedSanofiSmall moleculeBlocker5
      GlyburideApprovedPfizerSmall moleculeBlocker5
      GlipizideApprovedPfizerSmall moleculeBlocker4
      TolbutamideApprovedJiangsu Simcere Pharmaceutical Co., Ltd.Small moleculeBlocker1
      AcetohexamideApprovedEli LillySmall moleculeBlocker0
      ChlorpropamideApprovedPfizerSmall moleculeBlocker0
      NateglinideApprovedNovartis PharmaceuticalsSmall moleculeBlocker0
      TolazamideApprovedPfizerSmall moleculeBlocker0
      MitiglinidePhase 3Elixir PharmaceuticalsSmall moleculeBlocker0
      Mitiglinide calcium dihydratePhase 3Kissei Pharmaceutical Co., Ltd.OtherBlocker0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
      Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 DiabetesGliclazidePhase 2RecruitingUniversitas SriwijayaNov 10, 2026
      Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerRepaglinide, TolbutamidePhase 1Not yet recruitingJiangsu Simcere Pharmaceutical Co., Ltd.Nov 3, 2026
      A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseGlimepiride, Glipizide, GliclazidePhase 2Active, not recruitingBeijing University of Chinese MedicineOct 30, 2026
      A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsRepaglinidePhase 1RecruitingBasilea PharmaceuticaOct 19, 2026
      Comparison of Metformin Versus Glyburide for Blood Sugar Control in Women With Gestational DiabetesGlyburidePhase 4RecruitingNishtar Medical UniversitySep 3, 2026
      Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRepaglinidePhase 4RecruitingRigel PharmaceuticalsJul 15, 2026
      Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3GlimepirideNot applicableRecruitingWashington University School of MedicineMay 15, 2026
      A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.RepaglinidePhase 1RecruitingPMV Pharmaceuticals, IncJan 28, 2026
      Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus PatientsGlimepiridePhase 4Not yet recruitingChong Kun Dang PharmaceuticalJan 26, 2026
      A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRepaglinidePhase 1RecruitingNovartis PharmaceuticalsJan 14, 2026
      Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.GlimepiridePhase 3Not yet recruitingTongji HospitalDec 17, 2025
      OER Glibenclamide for Neuropathic Pain in Multiple SclerosisGlyburidePhase 1Not yet recruitingUniversity of Maryland, BaltimoreOct 28, 2025
      A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRepaglinidePhase 1 / Phase 2RecruitingVerastem, Inc.Jun 13, 2025
      Diabetes Management for Primary Healthcare Centers.GlyburideNot applicableActive, not recruitingUniversity of AbujaApr 2, 2025
      Role of KATP Channel Loss in Type 2 DiabetesGlipizideNot applicableRecruitingWashington University School of MedicineFeb 17, 2025
      Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease PatientsRepaglinide, GliclazideEarly phase 1Not yet recruitingLiu ZhanghongJan 28, 2025
      Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 DiabetesGliclazidePhase 4RecruitingUniversity Medical Centre LjubljanaSep 26, 2024
      A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic CancerGlipizidePhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterDec 13, 2023
      Spinal Cord Injury Neuroprotection With GlyburideGlyburidePhase 1RecruitingFrancis FarhadiJun 22, 2022
      A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)RepaglinidePhase 1 / Phase 2RecruitingNuvalent Inc.May 20, 2022
      Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyGlimepiride, Glipizide, Glyburide—Active, not recruitingBrigham and Women's HospitalFeb 2, 2022
      HbA1c Variability in Type II DiabetesGliclazideNot applicableActive, not recruitingWeill Cornell Medical College in QatarAug 25, 2016

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096972, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.